Dubai Research Guide — BPC-157

BPC-157 Dubai: Research Vial & Evidence Guide

What is sold as BPC-157 in Dubai, what the cell, animal and human evidence does and does not show, where regulators stand in 2026, and how to check a supplier’s batch report.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 7, 2026: Corrected the human-data record to the five studies in FDA's briefing (two abstract-only placebo-controlled enema studies from 2002–2005, plus three uncontrolled pilot reports).
October 7, 2026: Initial publication, built from FDA's May 2026 briefing document, the July 2026 advisory-committee record, WADA lists, ClinicalTrials.gov and a source-by-source check of the BPC-157 literature.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

BPC-157 is a synthetic 15-amino-acid peptide with a large rat literature, five small human studies (two placebo-controlled enema studies reported only as conference abstracts and three uncontrolled pilot reports), and no controlled trial showing efficacy. It is not an approved medicine in any country; FDA said so in its May 2026 review.[1][2][3] In July 2026 an FDA advisory committee narrowly recommended allowing US compounding pharmacies to use it for ulcerative colitis, against the advice of FDA's own reviewers. The vote is not binding, and no final FDA decision has followed.[4][5] WADA has named it as a prohibited substance since 2022.[6]

In Dubai the name covers three different products: clinic "peptide therapy" sessions, research-use vials and pens from peptide suppliers, and oral supplement capsules on marketplaces. This guide is about checking the second kind. Remy Research lists the BPC-157 10mg vial at AED 220 (AED 180 at the 5+ tier) to a ≥99% HPLC line standard, with no batch-specific Janoshik report published yet. Material is supplied for in-vitro laboratory research only — not for human or veterinary use.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is Sold as "BPC-157" in Dubai

A search for BPC-157 in Dubai returns three kinds of offer that are easy to confuse:

Identity, Salt Forms and Label Mass

BPC-157 is a 15-residue peptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). PubChem lists the free base as C62H98N16O22, about 1419.5 g/mol, CAS number 137525-51-0, PubChem CID 9941957.[1] It was first described in 1993 by a Zagreb group as a partial sequence of a protein found in human gastric juice, and most of the literature since comes from that group.[7]

Salt form matters on a certificate. FDA's 2026 review covered the free base and the acetate, and noted that the certificates submitted for "BPC-157" were in fact for the acetate.[2] "Arginate" or "stable" BPC-157 is sold as a separate form; arginate salts appear in the developers' patents, but no peer-reviewed study characterising them was found.[3] In the literature, "stable gastric pentadecapeptide" describes the peptide's stability in gastric juice, not a salt. And "10mg" on a label usually means powder mass, including counter-ion and water, not peptide content.

The Evidence, Sorted by Type

The mechanism and preclinical studies are reviewed in depth in the BPC-157 research review. For a sourcing decision, what matters is which kind of evidence supports which claim.

Evidence type What exists What it can show
Cell studies Tendon fibroblast survival and migration; VEGFR2 signalling in endothelial cells Possible mechanisms only
Animal studies Dozens of rat models of tendon, ligament, gut and blood-vessel injury, mostly from one group Hypotheses for human study
Human pilots Three uncontrolled reports by one Florida physician: knee pain, interstitial cystitis, a two-person IV safety check Feasibility, not efficacy
Controlled trials Two placebo-controlled enema studies (2002–2005), reported only as conference abstracts and judged inadequate by FDA; a US placebo-controlled trial is planned to start in 2027 No efficacy shown

In rats, BPC-157 improved healing of a cut Achilles tendon; in cell work it supported tendon-fibroblast survival and migration, and in endothelial cells it activated VEGFR2 signalling.[8][9][10] A 2025 systematic review of its use in sports medicine included 36 studies, of which 35 were preclinical and one clinical.[11] The human reports are a retrospective knee-pain chart review, a 12-patient interstitial cystitis pilot and a two-person intravenous safety pilot, all without control groups.[12][13][14] A 2025 review concluded BPC-157 should be considered investigational.[15] On ClinicalTrials.gov, a 2015 phase 1 study has an unknown status with no results posted, and a sham-controlled rotator-cuff trial at the University of Arkansas is planned to start in 2027. A further "recruiting" record is not counted here: its sponsor's other registrations include a study titled "Mock Study" and a copy of an existing drug-company trial.[16]

What Has Been Published on Safety

Regulatory Status in 2026

Where BPC-157 stands as of October 7, 2026.
  • United States. Not an FDA-approved drug, and FDA reports no approved BPC-157 product in any country. It was removed from FDA's Category 2 compounding list in 2026 after its nominations were withdrawn, and FDA then reviewed it on its own initiative.[20] On July 23, 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List for ulcerative colitis, reportedly 8 to 6 with one abstention. FDA's reviewers had recommended against it. The vote is non-binding, and no final FDA action had been published by October 7, 2026.[21][5]
  • European Union. No centrally authorised BPC-157 product.[22]
  • United Arab Emirates. We could not find BPC-157 registered as a medicine in the UAE. This is not a legal opinion; see the Dubai legality brief.
  • Sport. Prohibited at all times under WADA class S0 (non-approved substances), where it is named as an example, from the 2022 List through the 2027 List that takes effect on January 1, 2027. Anti-doping laboratories have a validated urine test.[23][24]

BPC-157 at Remy Research: Dubai Listing Facts

The product pages are the source of truth for price and stock. The table records the catalogue as of October 7, 2026.

Product Format and AED tiers Documentation
10mg vial Lyophilised powder, sealed glass vial · AED 220 · 2+ AED 200 · 5+ AED 180 · in stock ≥99% HPLC line standard; no batch-specific Janoshik report published
20mg pen Pre-filled pen · AED 400 · 2+ AED 370 · 5+ AED 340 · in stock ≥99% HPLC line standard; no batch-specific Janoshik report published
Genovare 25mg pen Aqueous pre-filled pen · AED 550 · in stock Independent testing not supplied
BPC-157 + TB-500 Blend vial and Genovare blend pen; see the blend guide See each product page

Remy Research publishes batch-specific Janoshik reports for its Retatrutide products in the lab results library. The BPC-157 line is not yet covered by a published batch report, and this page does not imply otherwise. Delivery terms across the emirates are on the delivery page.

Checking a BPC-157 Supplier in the UAE

Many UAE listings show a purity image with no date, lab name or batch number. FDA's own review found that a purity figure alone left impurities, aggregates and endotoxin unanswered.[2] Before ordering from any supplier, including this one, check:

What This Page Does Not Claim

Our Research Standards

This guide relies on regulator records, FDA's 2026 briefing document and primary literature, each checked on October 7, 2026, and keeps cell, animal and human evidence separate. Listing facts come from the Remy Research catalogue on the same date. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

BPC-157 Dubai FAQ

Where can I buy BPC-157 in Dubai?

In Dubai it is offered as clinic "peptide therapy", as research-use-only vials and pens from peptide suppliers, and as supplement capsules on marketplaces. For research material, Remy Research lists a 10mg vial, a 20mg pen and a Genovare 25mg pen, supplied for in-vitro laboratory research only and not for human or veterinary use. Whatever the source, ask for a dated, batch-linked certificate with mass-spectrometry identity before ordering.

Is BPC-157 legal in the UAE?

We could not find BPC-157 registered as a medicine in the UAE, and FDA reports no approved BPC-157 product in any country. This is a status line, not legal advice; the Dubai legality brief covers the wider rules.[2]

Is BPC-157 FDA-approved?

No. On July 23, 2026 an FDA advisory committee voted, reportedly 8 to 6 with one abstention, to recommend allowing US compounding pharmacies to use it for ulcerative colitis, against FDA reviewers' advice. The vote is non-binding, and no final FDA action had been published by October 7, 2026.[21][5]

Has BPC-157 been tested in humans?

Only in small studies. FDA's briefing for the July 2026 advisory meeting lists five: two placebo-controlled enema studies from 2002–2005, reported only as conference abstracts, and three uncontrolled pilot reports by one Florida physician (a knee-pain chart review, a 12-patient interstitial cystitis pilot and a two-person intravenous safety pilot). No controlled trial has shown efficacy; a US sham-controlled trial is planned to start in 2027.[2][12][13][14][16]

Is BPC-157 banned in sport?

Yes. WADA names BPC-157 under class S0, non-approved substances, prohibited at all times. It has been named since the 2022 List and remains on the 2027 List. A validated urine detection method exists.[23][24]

What should a BPC-157 certificate of analysis show?

Identity by mass spectrometry, HPLC purity, ideally net peptide content and the salt form, the lab name, a date and a batch number that matches the vial. FDA noted that certificates it reviewed gave purity without impurity, aggregate or endotoxin data, which is why a "99%" figure alone is not enough.[2]

What is the difference between BPC-157 acetate and arginate?

Both are salt forms of the same 15-amino-acid peptide. The acetate is the form FDA reviewed in 2026 and the one most certificates report. Arginate salts appear in the developers' patents, but no peer-reviewed study characterising them was found, so claims that one form works better are unsupported.[2][3]

Is BPC-157 from Amazon or noon the same as a research vial?

No. Marketplace listings are oral capsules sold as supplements. FDA found no human pharmacokinetic data for the oral route, and these products are not research-grade peptide supplied with a batch certificate.[2]

Sources

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957, BPC-157 (C62H98N16O22, 1419.5 g/mol; CAS 137525-51-0). Accessed October 7, 2026. pubchem.ncbi.nlm.nih.gov/compound/9941957 ↩
  2. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: BPC-157-related bulk drug substances (BPC-157 free base and BPC-157 acetate), dated May 11, 2026. fda.gov/media/193343 ↩
  3. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi: 10.3390/ph18020185 · PMID: 40005999 ↩
  4. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895, meeting materials). Accessed October 7, 2026. fda.gov ↩
  5. Liang L. Peptides: US advisory committee recommends six for FDA "compounding list". BMJ. 2026;394:e100422. doi: 10.1136/bmj-2026-100422 · PMID: 42521352 ↩
  6. World Anti-Doping Agency. WADA's 2022 Prohibited List now in force (BPC-157 first named in S0). January 1, 2022. wada-ama.org ↩
  7. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. doi: 10.1016/0928-4257(93)90038-u · PMID: 8298609 ↩
  8. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi: 10.1016/S0736-0266(03)00110-4 · PMID: 14554208 ↩
  9. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi: 10.1152/japplphysiol.00945.2010 · PMID: 21030672 ↩
  10. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi: 10.1007/s00109-016-1488-y · PMID: 27847966 ↩
  11. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi: 10.1177/15563316251355551 · PMID: 40756949 ↩
  12. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435 ↩
  13. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560 ↩
  14. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143 ↩
  15. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi: 10.1007/s12178-025-09990-7 · PMID: 40789979 ↩
  16. U.S. National Library of Medicine. ClinicalTrials.gov records for BPC-157, including NCT02637284 (phase 1, status unknown) and NCT07803250 (rotator-cuff repair, not yet recruiting) (API v2 query, October 7, 2026). clinicaltrials.gov ↩
  17. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi: 10.1016/j.yrtph.2020.104665 · PMID: 32334036 ↩
  18. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi: 10.3389/fphar.2022.1026182 · PMID: 36588717 ↩
  19. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. doi: 10.1007/s40279-026-02437-0 · PMID: 41966639 ↩
  20. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (BPC-157 listed under "nominated but withdrawn"), page modified April 22, 2026. fda.gov ↩
  21. Choi J. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. The Hill. July 23, 2026. thehill.com ↩
  22. European Medicines Agency. Medicines data (centrally authorised medicines; no BPC-157 product listed). Accessed October 7, 2026. ema.europa.eu ↩
  23. World Anti-Doping Agency. WADA publishes 2027 Prohibited List (S0 Non-approved substances names BPC-157; in force January 1, 2027). September 21, 2026. wada-ama.org ↩
  24. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. doi: 10.1002/dta.2152 · PMID: 28035768 ↩

For current stock and price, use the BPC-157 10mg vial page. For the full mechanism and preclinical review, see the BPC-157 research review; for wider sourcing checks, the Dubai research-vial map.

Related Research

Profile BPC-157 Research Review→ Compare BPC-157 vs TB-500→ Product BPC-157 10mg Research Vial→ Dubai Guide TB-500 Dubai Guide→ Dubai Guide BPC-157 + TB-500 Blend Dubai Guide→ Cluster Hub Healing & Recovery Peptides→ Verification How to Verify a Janoshik COA→ Compliance Are Peptides Legal in Dubai?→ Blend GLOW 70mg Pen Dubai: Blend Rationale, Pricing & Stock Status →